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Summary
Background A sexual dimorphism exists in the incidence and prevalence of coronary artery disease—men are more 
commonly aﬀ ected than are age-matched women. We explored the role of the Y chromosome in coronary artery 
disease in the context of this sexual inequity.
Methods We genotyped 11 markers of the male-speciﬁ c region of the Y chromosome in 3233 biologically unrelated 
British men from three cohorts: the British Heart Foundation Family Heart Study (BHF-FHS), West of Scotland 
Coronary Prevention Study (WOSCOPS), and Cardiogenics Study. On the basis of this information, each 
Y chromosome was tracked back into one of 13 ancient lineages deﬁ ned as haplogroups. We then examined 
associations between common Y chromosome haplogroups and the risk of coronary artery disease in cross-sectional 
BHF-FHS and prospective WOSCOPS. Finally, we undertook functional analysis of Y chromo some eﬀ ects on 
monocyte and macrophage transcriptome in British men from the Cardiogenics Study.
Findings Of nine haplogroups identiﬁ ed, two (R1b1b2 and I) accounted for roughly 90% of the Y chromosome variants 
among British men. Carriers of haplogroup I had about a 50% higher age-adjusted risk of coronary artery disease 
than did men with other Y chromosome lineages in BHF-FHS (odds ratio 1·75, 95% CI 1·20–2·54, p=0·004), 
WOSCOPS (1·45, 1·08–1·95, p=0·012), and joint analysis of both populations (1·56, 1·24–1·97, p=0·0002). The 
association between haplogroup I and increased risk of coronary artery disease was independent of traditional 
cardiovascular and socioeconomic risk factors. Analysis of macrophage transcriptome in the Cardiogenics Study 
revealed that 19 molecular pathways showing strong diﬀ erential expression between men with haplogroup I and 
other lineages of the Y chromosome were interconnected by common genes related to inﬂ ammation and immunity, 
and that some of them have a strong relevance to atherosclerosis.
Interpretation The human Y chromosome is associated with risk of coronary artery disease in men of European 
ancestry, possibly through interactions of immunity and inﬂ ammation.
Funding British Heart Foundation; UK National Institute for Health Research; LEW Carty Charitable Fund; National 
Health and Medical Research Council of Australia; European Union 6th Framework Programme; Wellcome Trust.
Introduction
Of all human chromosomes, the haploid Y chromosome 
contains the smallest number of genes. The main part 
of the Y chromosome (male-speciﬁ c region; MSY) is 
transmitted intact from father to son and contains single 
and multicopy genes that encode about 27 distinct 
proteins.1,2 The fundamental biological role of the 
Y chromosome is to impart male characteristics.3 
However, there are also data linking the Y chromosome 
to the cardiovascular system. For example, polysomy of 
the Y chromosome (mostly 47, XYY karyotype) was linked 
to increased cardiovascular mortality,4 and a common 
biallelic polymorphism of the MSY was associated with 
blood pressure, circulating concentrations of total 
cholesterol, LDL cholesterol, proatherogenic B-phenotype 
of LDL cholesterol molecules, and paternal history of 
coronary artery disease.5–8 Although not all studies have 
replicated these associations, the accumulated evidence9,10 
lends support to the notion that genetic variation within 
the MSY could play a part in determining cardiovascular 
risk in men. In view of the haploid nature of the MSY 
and its low level of recombination, the usual methods of 
linkage disequilibrium-based mapping applied to auto-
somal chromosomes cannot be used in investigation 
of its variation. The most appropriate strategy is the 
analysis of the Y chromosome phylogenetic tree. Deﬁ ned 
by a series of biallelic single nucleotide polymorphisms 
(SNPs), MSY can be partitioned into 20 major haplo-
groups that descend from a common ancestor, 
Y-chromosomal Adam.2
We directly examined association between the Y chromo-
some and coronary artery disease. We ﬁ rst examined 
whether common Y chromosome haplo groups were 
associated with risk of coronary artery disease in white 
British men recruited into the cross-sectional British 
Heart Foundation Family Heart Study (BHF-FHS).11 We 
next evaluated the association of Y chromo some lineages 
with prospective development of coronary artery disease 
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in the West of Scotland Coronary Prevention Study 
(WOSCOPS), a clinical trial that examined the beneﬁ ts 
of statin treatment for primary prevention of coronary 
artery disease in middle-aged Scottish men.12,13 Finally, we 
explored the signatures of Y-chromosomal evolution on 
the human transcriptome in monocytes and macro phages 
from British men recruited into the Cardiogenics Study.14
Methods
Genetic association analysis
The cross-sectional case-control analysis included 
811 men with coronary artery disease recruited into 
BHF-FHS and 633 male controls from the UK Blood 
Service collection of common controls, which is part of 
the Wellcome Trust Case Control Consortium (WTCCC). 
Cases in the BHF-FHS had a validated history of 
coronary artery disease, deﬁ ned as myocardial infarction 
or angina (veriﬁ ed by exercise stress test or angiography) 
or coronary artery bypass surgery or percutaneous trans-
luminal coronary angioplasty before their 66th birthday 
and a strong family history of coronary artery disease 
with at least one similarly aﬀ ected sibling.11 In the present 
analysis we used an available subsample of biologically 
unrelated men from the original collection. The control 
participants had no known history of coronary artery 
disease and were recruited nationally in equal proportions 
in each decade from 30 to 70 years. Apart from sex, age 
group, and geographic region, no other information was 
available for the controls. Both cases and controls were 
previously genotyped with Aﬀ ymetrix GeneChip Human 
Mapping 500K Array (Santa Clara, USA; in the WTCCC 
genome-wide association studies)15 and, more recently, 
with Illumina HumanCVD BeadChip array (50K IBC 
array; San Diego, USA).16
In the original WOSCOPS, 6595 statin-naive men aged 
45–64 years (mean 55·2 years), who had total serum 
cholesterol between 6·5 and 7·8 mmol/L at recruitment, 
an LDL cholesterol greater than 4·5 mmol/L on one 
occasion before randomisation, and no history of myo-
cardial infarction were assigned to receive 40 mg of 
pravastatin or placebo daily. During a mean follow-up of 
4·9 years, 503 participants had a primary endpoint event 
(a composite of non-fatal myocardial infarction and 
death from coronary artery disease) and 77 further men 
had a coronary revascularisation procedure.13 These 
580 men were regarded as cases for the purpose of 
nested case-control studies done here. They were each 
matched with two participants (controls) who remained 
event-free during the study on the basis of age (with 
2-year age categories), duration of follow-up, and 
smoking status, as previously described. Altogether, 
1740 men (580 cases and 1160 controls) were identiﬁ ed 
for the nested case-control analysis.12 Leucocyte DNA, 
extracted from blood collected at recruitment, was avail-
able for 1542 participants (484 cases and 1058 controls). 
The demographic characteristics of the missing samples 
were similar to those studied (data not shown). Geno-
typing for the Y chromosome SNPs was successful in 
1534 men (482 cases and 1052 controls) and these 
individuals were included in the genetic association 
analysis. All major risk factors were assessed during 
recruitment, as described previously. Information about 
socioeconomic factors (Carstairs deprivation index, 
educational attainment, employment status) was also 
reported before.17
Transcriptomic analysis
The Cardiogenics Study is a European collaboration on 
genetics of coronary artery disease.14 This initiative 
recruited 918 participants (459 patients with myocardial 
infarction and 459 normal controls) in ﬁ ve centres: 
Cambridge (UK), Leicester (UK), Lübeck (Germany), 
Regensburg (Germany), and Paris (France).14 1533 samples 
(849 from monocytes and 684 from macrophages) were 
available for RNA-based analysis. The mRNA expression 
studies for the present project were undertaken in 255 men 
selected from all participants (134 patients with premature 
myocardial infarction and 121 normal controls). Selection 
was determined by male sex, origin (British), and 
availability of both DNA and RNA information. All 
participants were of white European origin. 
All studies complied with the Declaration of Helsinki 
and were approved by their local ethics committee and 
participants gave written informed consent.
DNA analysis
On the basis of a study of Y chromosome diversity in the 
British population,18 we selected 11 biallelic SNPs (M9, 
M35, M45, M89, M170, M173, M201, M207, M269, M304, 
and SRY10831) for genotyping (webappendix p 2). Together, 
these markers deﬁ ne haplogroups that account for 
more than 95% of MSY lineages in the UK.19 On the basis 
of the hierarchical conﬁ guration of the 11 poly morphisms, 
each Y chromosome was assigned into one of 13 major 
European haplogroups named according to the 
Y Chromosome Consortium nomenclature.20 DNA was 
extracted from peripheral leucocytes. Genotyping was 
done with TaqMan assays on an ABI PRISM 7900HT 
Sequence Detection System (Applied Biosystems, 
Warrington, UK). Discrimination of genotypes was done 
with Applied Biosystems software.
Monocyte and macrophage isolation and RNA analysis
Monocytes were isolated from whole blood by positive 
selection with CD14 magnetic beads using an AutoMACS 
system (Miltenyi Biotech, Bergisch Gladbach, Germany).21 
Cell purity was conﬁ rmed by ﬂ ow cytometry and in all 
samples more than 90% of cells were CD14-positive 
monocytes.21 Macrophages were obtained from culturing 
of monocytes for 7 days in macrophage-SFM medium 
(Gibco/Invitrogen, Grand Island, USA) with 50 ng/mL 
recombinant human M-CSF (R&D Systems, Minneapolis, 
USA).14 RNA was extracted from both monocytes and 
macrophages with TRIzol, followed by clean-up with 
See Online for webappendix
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RNeasy columns (Qiagen, Venlo, Netherlands) and 
DNase-based treatment.21 Monocyte, macro phage, and 
RNA isolation were done separately in each centre using 
standardised procedures. Further micro array gene-
expression proﬁ ling of all samples was done in one 
centre (Paris, France). None of the samples of RNA from 
the monocytes or macrophages was pooled. Each was 
run as an individual sample on the Illumina Human 
Ref-8 arrays (Illumina, San Diego, USA) containing 
24 516 probes.14 The mRNA was ampliﬁ ed and labelled 
with the Illumina Total Prep RNA Ampliﬁ cation Kit 
(Ambion, Austin, USA).14 After hybridisation, array 
images were scanned with an Illumina BeadArray Reader 
and probe intensities were extracted with the gene 
expression module of Illumina Bead Studio software.21 
Variance stabilisation transformation was applied to the 
raw intensities and quantile normalisation was done 
in the R statistical environment with the Lumi and 
Beadarray packages (version 1.8.3).14 After quality control, 
12 145 probes with detectable levels of expression were 
included in the analysis.
Statistical and bioinformatic analysis
The initial unadjusted analysis of association between 
Y chromosome haplogroups (haplogroup I vs all others) 
and coronary artery disease as well as other qualitative 
traits was done with the χ² test. The age-adjusted and fully 
adjusted (for available demographic and clinical variables) 
analyses were done with binary logistic regression models. 
Crude and age-adjusted comparisons of normally 
distributed continuous variables with Y chromosome 
haplogroups were done with t tests (crude comparison) 
and linear regression models (age-adjusted). Quantitative 
traits with non-Gaussian distributions (triglycerides and 
C-reactive protein) were analysed with the Mann-Whitney 
test and log-transformed before multiple regression. A 
ﬁ xed-eﬀ ect inverse-variance-weighted meta-analysis was 
used to combine the age-adjusted results from the BHF-
FHS and WOSCOPS studies.
To detect population stratiﬁ cation (which can lead to 
spurious associations), we used data for autosomal SNPs 
from BHF-FHS and Cardiogenics participants, genotyped 
with GeneChip Human Mapping 500K Array (Aﬀ ymetrix) 
in BHF-FHS and Human 610 Quad Custom array 
(Illumina) in Cardiogenics. The standard quality control 
ﬁ lters (SNPs with minor allele frequency <1%, Hardy-
Weinberg equilibrium χ² p<0·001 in controls, and call 
rate <95%) were applied before the analysis. Subsequently, 
correlated SNPs (those showing multiple correlation 
coeﬃ  cient ≥0·2) were removed from the data with PLINK 
software (version 1.07). The pruned subset of independent 
SNPs was used to calculate the genome-wide, identity-by-
state, distance matrix. This matrix was further trans-
formed with a non-metric, multidimensional scaling 
technique to visualise genetic similarity between 
participants of both cohorts (against three HapMap 
populations and stratiﬁ ed on the Y chromosome 
Cases Controls p value
BHF-FHS
n 811 633 ··
Age (years) 60·6 (7·5) 45·5 (11·7) <0·0001
WOSCOPS
n 482 1052 ··
Age (years) 56·9 (5·1) 56·8 (5·2) 0·533
Body-mass index (kg/m²) 26·0 (3·2) 25·6 (3·2) 0·026
Systolic blood pressure (mm Hg) 139·5 (17·2) 135·7 (17·1) 0·0001
Diastolic blood pressure (mm Hg) 85·5 (10·5) 83·7 (10·2) 0·001
HDL cholesterol (mmol/L) 1·1 (0·2) 1·1 (0·3) <0·0001
LDL cholesterol (mmol/L) 5·0 (0·5) 4·9 (0·4) 0·004
Triglycerides (mmol/L) 2·1 (1·6 to 2·8) 1·9 (1·5 to 2·6) 0·005
Pravastatin-based treatment 194 (40%) 539 (51%) 0·0001
Glucose (mmol/L) 4·9 (0·7) 4·8 (0·7) 0·025
Diabetes 9 (2%) 13 (1%) 0·464
C-reactive protein (mg/L) 2·7 (1·2 to 4·9) 1·9 (0·9 to 3·9) <0·0001
Smoking 258 (54%) 581 (55%) 0·571
Alcohol consumption ≥20 units per week 79 (16%) 186 (18%) 0·584
Carstairs deprivation index* 0·4 (–1·7 to 3·0) 0·5 (–1·8 to 3·0) 0·943
Highest educational attainment† 1·6 (0·9) 1·7 (0·9) 0·784
In employment 304 (63%) 690 (66%) 0·338
Data are n (%), mean (SD), or median (IQR). *Continuously scored measure based on four factors: lack of car 
ownership; Registrar General’s Social Class classiﬁ cation of IV or V; overcrowded households; and male unemployment. 
†Average score based on four categories: secondary school with leaving certiﬁ cate (no graduation); school leaving 
certiﬁ cate (with graduation); further education, but no degree; and university degree or similar.
Table 1: Characteristics of men from British Heart Foundation Family Heart Study (BHF-FHS) and West of 
Scotland Coronary Prevention Study (WOSCOPS) stratiﬁ ed by case-control status
Figure 1: Phylogenetic tree of the Y chromosome and frequency of haplogroups in the British Heart 
Foundation Family Heart Study (BHF-FHS) and West of Scotland Coronary Prevention Study (WOSCOPS)
Each vertical line represents one branch (haplogroup) of the Y chromosome phylogenetic tree. The 13 most 
common Y chromosome haplogroups are shown and are lined up from the phylogentically oldest on the left 
(Y[xBR]) to the youngest on the right (R1b1b2). The vertical length or height of each line corresponds to the age of 
each haplogroup (the longest line being the oldest haplogroup). The symbols at the top of each line (SRY10831.1, 
M35, M89, M201, M170, M304, M9, M45, M207, M173, SRY10831.2, and M269) are the identiﬁ cation numbers of 
the single nucleotide polymorphisms that deﬁ ne speciﬁ c haplogroups according to the Y Chromosome Consortium 
nomenclature. The numbers in boxes reﬂ ect prevalence (percentage) of each haplogroup in BHF-FHS (upper row) 
and WOSCOPS (lower row) populations.
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haplogroup). We also compared the ﬁ rst four dimensions 
extracted from the multidimensional scaling analysis 
between men with haplogroup I and carriers of the other 
haplogroups using t tests.
We also used data available from 1444 men in the BHF-
FHS to examine whether haplogroup I and other 
Y chromosome lineages diﬀ er in genotype distribution 
of SNPs associated with coronary artery disease in 
previous genome-wide association studies. We ﬁ rst 
identiﬁ ed 34 autosomal SNPs associated with coronary 
artery disease in three recent large-scale genetic 
studies.14,16,22 Of those, 21 were directly genotyped and 
13 were imputed with the IMPUTE algorithm, as reported 
before.23 Three SNPs were excluded from further analysis 
because of low (<80%) number of informative genotypes. 
Genotypes of 31 remaining SNPs were in Hardy-
Weinberg equilibrium. Diﬀ erences in distribution of the 
genotypes stratiﬁ ed on the Y chromosome haplogroup (I 
vs others) were examined by χ² test with Bonferroni 
correction (p=0·0016; 0·05/31 tests) for multiple testing. 
Binary logistic regression models with coronary artery 
disease as an independent variable and age, binarised Y 
haplogroup status and genotypes of each SNP were 
constructed individually in STATA (version 11).
To detect pathways with diﬀ erentially expressed genes 
between men of haplogroup I versus those in other 
haplogroups of the Y chromosome we used gene set 
enrichment analysis (GSEA)—a sensitive method for 
detection of both large and subtle changes in pathways 
avoiding the use of arbitrary cutoﬀ  values to deﬁ ne a list 
of signiﬁ cant genes. We converted the linear regression 
score for each gene into a preranked list as input to GSEA 
in preranked mode, using 1000 permutations to assess 
the false discovery rate and the Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathways from the 
Molecular Signatures Database (version 3.0).24 Since gene 
sets are not independent, the overlaps between signiﬁ cant 
gene sets were assessed with Enrichment Map (version 
1·0)25 plugin for Cytoscape (version 2.8.0),26 using gene 
sets with false discovery rate less than 0·2 and an overlap 
coeﬃ  cient of 0·3 or higher. The analysis was adjusted for 
age and coronary artery disease status and done separately 
in monocytes and macrophages.
Role of the funding source
The funders did not contribute to study design, data 
interpretation, editing of the report, or decision to 
submit. The corresponding author had full access to the 
data and ﬁ nal responsibility for the decision to submit 
for publication.
Results
Table 1 summarises the demographic and clinical 
characteristics of BHF-FHS and WOSCOPS men 
stratiﬁ ed by case-control status. In BHF-FHS, age (the 
only additional clinical phenotype available in both cases 
and controls) diﬀ ered signiﬁ cantly between men with 
coronary artery disease and controls. There were no 
signiﬁ cant diﬀ erences in age, smoking, alcohol 
consumption, employment status, highest education 
attainment, deprivation score, and prevalence of diabetes 
between cases and normal controls in WOSCOPS. By 
comparison with controls, men who developed coronary 
artery disease in WOSCOPS had signiﬁ cantly higher 
body-mass index (BMI), systolic and diastolic blood 
pressures, LDL cholesterol, triglycerides, C-reactive 
protein, and glucose concentrations, and lower HDL 
cholesterol levels (table 1).
To establish whether the Y chromosome is associated 
with coronary artery disease, we reconstructed the phylo-
genetic tree for the major Y chromosome haplogroups in 
both cohorts. Figure 1 shows the markers that deﬁ ne each 
haplogroup, together with the proportion of participants 
in each haplogroup. Of nine haplogroups identiﬁ ed, two 
(R1b1b2 and I) accounted for about 90% of variation in 
the Y chromosome in both studies. In BHF-FHS, 
haplogroup I was signiﬁ cantly more common in men 
with coronary artery disease than in controls (20% [n=166] 
vs 13% [n=80], p=0·0001). Age-adjusted analysis conﬁ rmed 
that, com pared with other haplo groups, I was associated 
with increased risk of coronary artery disease (odds ratio 
[OR] 1·75, 95% CI 1·20–2·54, p=0·004). To conﬁ rm and 
further validate these ﬁ ndings using a prospective design, 
Haplogroup I Other haplogroups p value
BHF-FHS
n 246 1198 ··
Age (years) 55·8 (11·2) 53·6 (12·3) 0·006
WOSCOPS
n 228 1306 ··
Age (years) 57·3 (5·2) 56·7 (5·2) 0·133
Body-mass index (kg/m²) 25·6 (3·7) 25·8 (3·1) 0·469
Systolic blood pressure (mm Hg) 138·0 (15·9) 136·7 (17·4) 0·284
Diastolic blood pressure (mm Hg) 84·2 (10·1) 84·2 (10·4) 0·987
HDL cholesterol (mmol/L) 1·1 (0·3) 1·1 (0·3) 0·310
LDL cholesterol (mmol/L) 5·0 (0·5) 5·0 (0·4) 0·514
Triglycerides (mmol/L) 1·9 (1·6 to 2·6) 1·9 (1·5 to 2·6) 0·481
Pravastatin-based treatment 110 (48%) 623 (48%) 0·937
Glucose (mmol/L) 4·9 (0·8) 4·8 (0·7) 0·243
Diabetes 6 (3%) 16 (1%) 0·179
C-reactive protein (mg/L) 2·1 (1·1 to 4·0) 2·1 (1·0 to 4·3) 0·659
Smoking 115 (50%) 724 (55%) 0·185
Alcohol consumption ≥20 units per week 34 (15%) 231 (18%) 0·353
Carstairs deprivation index* 0·1 (–1·9 to 2·8) 0·5 (–1·7 to 3·0) 0·087
Highest educational attainment† 1·7 (0·9) 1·6 (0·9) 0·189
In employment 156 (68%) 838 (64%) 0·214
Data are n (%), mean (SD), or median (IQR). *Continuously scored measure based on four factors: lack of car 
ownership; Registrar General’s Social Class classiﬁ cation of IV or V; overcrowded households; and male unemployment. 
†Average score based on four categories: secondary school with leaving certiﬁ cate (no graduation); school leaving 
certiﬁ cate (with graduation); further education, but no degree; and university degree or similar.
Table 2: Characteristics of men from British Heart Foundation Family Heart Study (BHF-FHS) and West of 
Scotland Coronary Prevention Study (WOSCOPS) stratiﬁ ed by Y chromosome haplogroup status
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which is less subject to confounding than is the cross-
sectional design of BHF-FHS, we investigated participants 
recruited into WOSCOPS. In this cohort, haplogroup I 
was again signiﬁ cantly more common in men who 
developed coronary artery disease during a period of 
4·9 years than in matched controls who remained free of 
the disease (18% [n=88] vs 13% [n=140], p=0·014]. Age-
adjusted analy sis conﬁ rmed the association between 
haplogroup I and increased risk of coronary artery disease 
(OR 1·45, 95% CI 1·08–1·95, p=0·012) in this study. The 
WOSCOPS partici pants were extensively characterised for 
cardio vascular risk factors and traits (systolic and diastolic 
blood pressure, lipids, BMI, diabetes, C-reactive protein, 
glucose, alcohol consumption, smoking), pravastatin-
based treat ment, and socioeconomic factors at baseline. 
None of these phenotypes was signiﬁ cantly associated 
with haplogroup I in WOSCOPS (table 2). The binary 
logistic analysis showed that adjustment for these variables 
did not attenuate the association of haplogroup I with 
coronary artery disease (OR 1·60, 95% CI 1·16–2·19, 
p=0·004) and that after HDL cholesterol and lipid-lowering 
treatment, haplogroup I was the most signiﬁ cant predictor 
of coronary artery disease (webappendix p 3). A combined 
analysis of the age-adjusted eﬀ ects from the BHF-FHS 
study and WOSCOPS cohort showed that on average 
haplogroup I increased the risk of coronary artery disease 
by about 50% (OR 1·56, 95% CI 1·24–1·97, p=0·0002).
To exclude the presence of hidden admixture and 
population stratiﬁ cation as an explanation for the 
association of haplogroup I and coronary artery disease 
noted in BHF-FHS, we took advantage of genome-wide 
SNP data available for both cases and controls recruited 
into this study.15 Using non-metric multidimensional 
scaling of autosomal SNPs, we showed that all cases and 
controls in BHF-FHS showed evidence of European 
ancestry and there were no major diﬀ erences between 
men of haplogroup I and carriers of other Y chromosome 
haplogroups (webappendix pp 4, 14).
We also examined whether alleles of 31 autosomal 
SNPs associated with coronary artery disease genotyped 
with 500K Aﬀ ymetrix array and 50K IBC array showed 
diﬀ erent frequencies in carriers of haplogroup I and 
other MSY lineages. None of the SNPs showed diﬀ er-
ential distribution of genotypes after correction for 
multiple testing (webappendix p 5). We also conﬁ rmed 
that haplogroup I increased the risk of coronary artery 
disease, independent of the autosomal SNPs identiﬁ ed 
in previous genome-wide association studies; intro-
duction of each SNP (as an additional dependent 
variable) into the regression model did not attenuate the 
signiﬁ cance of association between haplogroup I and 
coronary artery disease (webappendix p 6).
In 255 Cardiogenics men included in the transcrip-
tomic analysis, those with coronary artery disease (cases) 
were signiﬁ cantly older and had higher BMI than did 
healthy controls (webappendix p 7). However, there were 
no diﬀ erences in either age or BMI between carriers of 
haplogroup I and other Y chromosome lineages in this 
population (webappendix p 8). To identify potential 
functional eﬀ ects of haplogroup I in cells of relevance to 
coronary artery disease we examined associations 
between Y chromosome haplogroups and both monocyte 
and macrophage transcriptome proﬁ les. We excluded the 
presence of population stratiﬁ cation and admixture in 
these participants, using the same approach as described 
earlier for the BHF-FHS cohort (webappendix pp 4, 14). 
The GSEA showed no diﬀ erences in monocyte trans-
criptome between men with haplogroup I and carriers of 
other MSY lineages after correction for multiple testing. 
By contrast, analysis of macrophage transcriptome identi-
ﬁ ed 30 KEGG pathways with diﬀ erential expression 
between haplogroup I and other lineages of the Y 
chromosome (false discovery rate <20%; webappendix 
pp 9–13). Of these, 19 pathways were interconnected by 
common genes related to inﬂ ammation and immunity; 
seven pathways were upregulated and 12 were down-
regulated in men with haplogroup I compared with 
carriers of other haplogroups (ﬁ gure 2).
Discussion
Our study is the ﬁ rst to evaluate associations between 
main European Y chromosome lineages and coronary 
artery disease as well as its underlying risk factors. The 
most important ﬁ nding from our analysis is that 
haplogroup I is associated with signiﬁ cantly increased 
risk of coronary artery disease compared with other 
ancient lineages of the Y chromosome and that this 
Figure 2: Immune pathways showing signiﬁ cant (false discovery rate <20%) diﬀ erential expression in 
macrophages from men with haplogroup I compared with carriers of all other haplogroups
Red nodes show upregulated pathways and blue nodes show downregulated pathways in men with haplogroup I 
from the Kyoto Encyclopedia of Genes and Genomes. Node size is a function of the number of genes in each 
pathway (the larger the node, the more genes in the pathway) and the colour intensity of each node reﬂ ects the 
level of signiﬁ cance. Lines represent a network of biological links between the pathways; the thickness of each line 
is proportional to number of genes shared by pathways connected by the line. The high interconnection between 
these pathways suggests that they are not independent and represent diﬀ erent, yet overlapping, facets of 
immunity (webappendix pp 9–13). The image was generated with the Enrichment Map plugin for Cytoscape. 
ECM=extracellular matrix.
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association, although independent of major cardio-
vascular risk factors and socioeconomic status, might be 
mediated through a genetically programmed proﬁ le of 
immunity and response to inﬂ ammation (panel).
Our transcriptomic analysis showed that several of 
19 pathways interconnected by inﬂ ammation and 
immunity genes, and showing diﬀ erential expression 
between men with haplogroup I and other lineages, 
might be relevant to atherosclerosis. Speciﬁ cally, traf-
ﬁ cking of leucocytes through the endothelial barrier is a 
well recognised process in both early27 and late28 stages of 
atherosclerosis, and leucocyte transendothelial migration 
(hsa04670) was identiﬁ ed as the most signiﬁ cantly 
upregulated pathway in gene expression proﬁ ling of 
atherosclerotic arterial wall.28 Focal adhesions (hsa04510) 
control cytoskeletal or adhesion dynamics and thus aﬀ ect 
both leucocyte motility within intima and interactions 
between platelets and endothelium, all of which play a 
part in the pathogenesis of coronary artery disease.29–31 
The balance between proinﬂ ammatory and anti-inﬂ am-
matory cytokines (cytokine-cytokine receptor interaction 
pathway, hsa04060) is also a well recognised mechan-
ism underlying atherosclerotic plaque develop ment.32 
Interest ingly, four of seven upregulated pathways (focal 
adhesion, cytokine-cytokine receptor interaction, hyper-
trophic cardiomyopathy [hsa05410], and extracel lular 
matrix-receptor interaction [hsa04512]) show the strongest 
enrichment for genes with previous evidence of 
association with coronary artery disease among more 
than 100 KEGG pathways.33 Pharmacological inhibitions 
of these pathways were suggested as treatments with 
a potential to reduce or even reverse the burden of 
atherosclerosis in coronary circulation.27,30,34 These mole-
cular networks therefore represent possible mechanisms 
explaining the association of haplogroup I with coronary 
artery disease. Furthermore, upregulation of these path-
ways in macrophages (but not in monocytes) suggests 
that diﬀ erentiation (activation) of monocytes to macro-
phages, one of the key steps in the pathogenesis of 
atherosclerosis,35 might be the stage at which haplogroup 
I exerts its molecular eﬀ ects on coronary artery disease.
Despite this attractive possibility, a statistically more 
striking ﬁ nding was the association of haplogroup I with 
downregulation of several pathways of the immune 
system. Indeed, some of the identiﬁ ed pathways are 
activated in exposure to pathogens (leishmaniasis 
[hsa05140], viral myocarditis [hsa05416]). Others directly 
represent immune response and processing (antigen 
processing and presentation [hsa04612] and intestinal 
immune network for IgA production [hsa04672]). Further-
more, some of the most signiﬁ cant pathways are in fact 
autoimmune disorders, including autoimmune thyroid 
disease (hsa05320) and type 1 diabetes (hsa09490). Most 
of the downregulated pathways interact together in 
regulation of adaptive immunity and operate mainly in 
lymphocytes or antigen-presenting cells, or both, possibly 
mostly through MHC class II cell surface receptors 
(HLA-DP, HLA-DQ, HLA-DR). Although not fully 
understood, dysfunction of immune response is a well 
established contributor to atherosclerosis and coronary 
artery disease.32 Previous studies suggested that the 
Y chromosome could play a part in regulation of the 
immune system—ie, men with haplogroup I of the 
Y chromosome were particularly vulnerable to HIV 
infection.36 In fact, carriers of haplo group I on retroviral 
therapy took a longer time to HIV suppression and had 
more accelerated progression to AIDS compared with 
carriers of other MSY lineages.36 Mortality from AIDS in 
men of haplogroup I was also signiﬁ cantly higher than 
that in men with other haplogroups.36
Taken together, these ﬁ ndings suggest that down-
regulation of adaptive immunity in carriers of haplogroup 
I is accompanied by upregulation of pathways underlying 
inﬂ ammatory response. This conclusion implies that 
haplogroup I carriers might have chronic derangements 
in homoeostatic mechanisms of adaptive immunity, 
possibly with heightened inﬂ ammation aﬀ ecting the 
cardiovascular system. A similar mechanism has been 
well documented in other complex disorders—ie, in 
inﬂ ammatory bowel disease, in which deﬁ ciencies 
in immunity status can lead to increased systemic 
inﬂ ammation.37 Interestingly, the association between 
haplogroup I and increased susceptibility to coronary 
Panel: Research in context
Systematic review
We searched original English-language publications in 
PubMed to May, 2011, using “Y chromosome”, “haplogroup”, 
“haplotype”, and “coronary artery disease” as keywords and 
found no studies that investigated the association between 
paternal lineages of the Y chromosome (haplogroups) and 
predisposition to coronary artery disease.
Interpretation
Our study is the ﬁ rst robust analysis of association between 
diﬀ erent lineages of the Y chromosome and coronary artery 
disease. We show that men who inherit haplogroup I (one of 
the most common Y chromosome types in Europe) from their 
male ancestors have a roughly 50% higher risk of coronary 
artery disease than do men with other types of the 
Y chromosome. The eﬀ ect of haplogroup I on coronary artery 
disease is not mediated by traditional cardiovascular risk factors 
such as age, body-mass index, blood pressure, lipids, diabetes, 
smoking, alcohol consumption, socioeconomic status, or 
circulating concentrations of C-reactive protein. However, we 
noted that men with haplogroup I showed downregulation of 
adaptive immunity as well as upregulation of inﬂ ammatory 
response pathways in their macrophages compared with 
carriers of other Y chromosome types. These data show that 
predisposition to coronary artery disease in men might, at least 
in part, be determined by the paternal lineage of their 
Y chromosome and that this eﬀ ect on risk of coronary artery 
disease is most likely mediated through immune response.
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artery disease was independent of C-reactive protein. 
This marker of inﬂ ammation is more closely related to 
innate than to adaptive defence mechanisms.38 Since the 
most distinct signature of haplogroup I in our study was 
identiﬁ ed on adaptive immunity pathways, we expect 
that studies with more robust markers of speciﬁ c 
immune system will be necessary to explain the 
association between the Y chromosome and coronary 
artery disease. Such investi gations should also take us 
closer to dissection of the mechanisms underlying the 
sex diﬀ erences in regulation of human immunity. 
Indeed, there is a well recognised sexual dimorphism in 
response to immunisation39 as well as susceptibility to 
autoimmune disorders.40 The biological background of 
these diﬀ erences is most likely multifactorial. Whether 
genes unique to the X chromo some, polymorphic 
variants of the MSY, their interactions with autosomal 
loci and environment, or all the above contribute to sex 
diﬀ erences in regulation of the immune system will need 
further studies to elucidate.
Evolutionarily, the distinguishing feature of haplo -
group I is its almost complete absence in indigenous 
populations outside Europe.2 The carriers of this 
haplogroup probably arrived from the Middle East as 
hunter-gatherers during the Paleolithic era roughly 
25 000 years ago and it has been suggested that they 
spread throughout Europe together with diﬀ usion of the 
Gravettian archaeological culture.41 The gradual Neolithic 
expansion of farmers 10 000 years ago led to the present 
dominance of R1b1b2 (over I and other MSY haplogroups) 
in most parts of northern and western Europe.2,42 The 
present geographical distribution of one of the major 
lineages of haplogroup I (I1) in western Europe correlates 
with the well established north–south gradient in 
prevalence of coronary artery disease. Indeed, in northern 
populations (Scandinavia, Germany, Netherlands) in 
which the prevalence of haplogroup I ranges between 
15% and 40%, mortality from coronary artery disease is 
signiﬁ cantly higher than in southern Europe (France, 
Apennine peninsula, Spain, and Switzerland), where 
haplogroup I is less prevalent (3–15%).43,44 The north–
south gradient in coronary artery disease morbidity was 
also reported in the UK (2011). Unavailability of 
information about birthplace of partici pants and their 
male ancestors and lack of samples from diﬀ erent parts 
of the UK prevented us from examining whether men 
with haplogroup I are over-represented in regions known 
for particularly high prev alence of coronary artery disease 
and its modiﬁ able lifestyle risk factors. Further studies 
should address the question of whether distribution of Y 
chromosome line ages could account (at least in part) for 
the geographic diﬀ er ences in predisposition to coronary 
artery disease in men.
We should acknowledge that similar to other common 
genetic variants associated with increased risk of cardio-
vascular disease, haplogroup I of the Y chromosome on its 
own is unlikely to oﬀ er suﬃ  ciently high positive predictive 
value of coronary artery disease. Indeed, single risk factors 
(both genetic and non-genetic) that are fairly common in 
both cases and controls and coupled with a 1·5-increase in 
the OR of a disease are not speciﬁ c enough as individual 
risk predictors.45,46 Nevertheless, the relative estimates of 
coronary artery disease risk in carriers of haplogroup I are 
not trivial from the point of view of genetic association 
analysis. Indeed, they are larger than that of many 
common autosomal alleles identiﬁ ed in recent genome-
wide association studies. Further replication of our results 
in large, prospective population-based studies is necessary 
to provide precise estimates of coronary artery disease risk 
attributable to variation in the Y chromosome. Such 
studies could have important public health implications 
in view of the signiﬁ cant lifetime risk of coronary artery 
disease in men47 and still imperfect risk stratiﬁ cation on 
the basis of traditional cardiovascular risk factors.46
A gap remains in the understanding of disease 
diﬀ erences both within and between populations. Here, 
we have identiﬁ ed an association that supports the hypo-
thesis that the Y chromosome determines inter individual 
diﬀ erences in susceptibility to coronary artery disease 
among British men. We also showed that this association 
could be mediated through immunity and inﬂ ammation-
related networks. Our study revealed that the Y chromo-
some might have a magniﬁ ed eﬀ ect on men beyond sex 
determination despite the small number of genes it 
harbours in the human genome. Future resequencing 
eﬀ orts and functional experiments will be needed to 
identify the causative variants underlying the increased 
susceptibility to coronary artery disease in carriers of haplo-
group I and to decipher complex interplay between human 
Y chromosome, immunity, and cardio vascular disease.
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